3 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 86 points (-0.5%) at 16,084 as of Friday, April 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,014 issues advancing vs. 1,941 declining with 158 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.5%, and Novo Nordisk A/S ( NVO), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.81 (-1.0%) to $83.02 on average volume. Thus far, 929,559 shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $82.70-$83.45 after having opened the day at $82.94 as compared to the previous trading day's close of $83.83.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $203.9 billion and is part of the health care sector. Shares are up 4.3% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Novartis a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)